BENZEKRY, Sébastien; BARBOLOSI, Dominique; BENABDALLAH, Assia; HUBERT, Florence; HAHNFELDT, Philip

Métadonnées

Afficher la notice complète

Licence d’utilisation du document

BENZEKRY, Sébastien
Center of Cancer and Systems Biology [CCSB]
Modélisation, contrôle et calcul [MC2]

BARBOLOSI, Dominique
Centre de Recherches en Oncologie biologique et Oncopharmacologie [CRO2]

BENABDALLAH, Assia
Laboratoire d'Analyse, Topologie, Probabilités [LATP]

Langue

Document de travail - Pré-publication

Résumé en anglais

A mathematical model for time development of metastases and their distribution in size and carrying capacity is presented. The model is used to theoretically investigate anti-cancer therapies such as surgery and chemical treatments (cytotoxic or anti-angiogenic), in monotherapy or in combination. Quantification of the effect of surgery on the size distribution of metastatic colonies is derived. For systemic therapies, emphasis is placed on the differences between the treatment of an isolated lesion and a population of metastases. Combination therapy is addressed, in particular the problem of the drugs administration sequence. Theoretical optimal schedules are derived that show the superiority of a metronomic administration scheme (defined as a continuous administration of a given amount of drug spread during the whole therapeutic cycle) on a classical Maximum Tolerated Dose scheme (where the dose is given as a few concentrated administrations at the beginning of the cycle), for the total metastatic burden in the organism.< Réduire

Mots clés en anglais

Metastases

Mathematical modeling

Anti-cancer therapy

Anti-angiogenesis

Metronomics

Origine

Importé de hal

Unités de recherche

Institut de Mathématiques de Bordeaux (IMB) - UMR 5251